FDA Clearance Tracker · P890003-S252
CARELINK MONITOR MODEL 2490G, CARDIOSIGHT READER
Last checked: Nov 20, 2026Latest source record: Jan 15, 2013 (this decision)Source: openFDAMethods & limitations
Decided
Jan 15, 2013
Approved
Time to decision
200 days
Received Jun 29, 2012. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P890003-S252
- Device name
- CARELINK MONITOR MODEL 2490G, CARDIOSIGHT READER
- Applicant
- Medtronic, Inc.
- Applicant location
- Mounds View, MN
- Received
- Jun 29, 2012
- Decided
- Jan 15, 2013
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P890003
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
APPROVAL OF AN MR-CONDITIONAL SYSTEM PERMITTING IMPLANTED PATIENTS TO UNDERGO MRI SCANS PROVIDED SPECIFIED CONDITIONS ARE MET. THE DEVICES, AS MODIFIED, MAKE UP THE ADVISA DR MRI SURESCAN SYSTEM AND WILL BE MARKETED UNDER THE TRADE NAMES ADVISA DR MRI A2DR01 IMPLANTABLE PULSE GENERATOR WITH SOFTWARE MODEL 9995, CARELINK MONITOR MODEL 2490G, CARDIOSIGHT READER MODEL 2020A AND DDMA MODEL 2491. THE ADVISA DR MRI SURESCAN SYSTEM IS INDICATED FOR THE FOLLOWING: 1) RATE ADAPTIVE PACING IN PATIENTS WHO MAY BENEFIT FROM INCREASED PACING RATES CONCURRENT WITH INCREASES IN ACTIVITY; AND2) ACCEPTED PATIENT CONDITIONS WARRANTING CHRONIC CARDIAC PACING INCLUDE: A) SYMPTOMATIC PAROXYSMAL OR PERMANENT SECOND-OR THIRD-DEGREE A V BLOCK; B) SYMPTOMATIC BILATERAL BUNDLE BRANCH BLOCK;C) SYMPTOMATIC PAROXYSMAL OR TRANSIENT SINUS NODE DYSFUNCTIONS WITHOR WITHOUT ASSOCIATED A V CONDUCTION DISORDERS D) BRADYCARDIA-TACHYCARDIA SYNDROME TO PREVENT SYMPTOMATIC BRADYCARDIA OR SOME FORMS OF SYMPTOMATIC TACHYARRHYTHMIAS; AND E) VASOVAGAL SYNDROMES OR HYPERSENSITIVE CAROTID SINUS SYNDROMES THE DEVICE IS ALSO INDICATED FOR DUAL CHAMBER AND ATRIAL TRACKING MODES IN PATIENTS WHO MAY BENEFIT FROM MAINTENANCE OF AV SYNCHRONY. DUAL CHAMBER MODES ARE SPECIFICALLY INDICATED FOR TREATMENT OF CONDUCTION DISORDERS THAT REQUIRE RESTORATION OF BOTH RATE AND AV SYNCHRONY, WHICH INCLUDE:1) VARIOUS DEGREES OF AV BLOCK TO MAINTAIN THE ATRIAL CONTRIBUTION TOCARDIAC OUTPUT; AND 2) VVI INTOLERANCE (FOR EXAMPLE, PACEMAKER SYNDROME) IN THE PRESENCE OF PERSISTENT SINUS RHYTHMANTITACHYCARDIA PACING (A TP) IS INDICATED FOR TERMINATION OF ATRIALTACHYARRHYTHMIAS IN BRADYCARDIA PATIENTS WITH ONE OR MORE OF THE ABOVE PACING INDICATIONS.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.